|Bid||153.50 x 1000|
|Ask||154.04 x 100|
|Day's Range||152.16 - 154.57|
|52 Week Range||133.64 - 184.21|
|PE Ratio (TTM)||14.63|
|Dividend & Yield||4.60 (2.94%)|
|1y Target Est||N/A|
Regeneron and Sanofi's rheumatoid arthritis drug is 15%-30% cheaper than rival drugs from Amgen, AbbVie and Roche, an analyst said Tuesday.
In 1Q17, Amgen’s (AMGN) Blincyto reported revenues of ~$34 million, which is equivalent to year-over-year sales growth of 26%.
Yesterday, Amgen (AMGN) dropped more than 2% after the trial for its osteoporosis drug revealed some safety issues with the drug. Today, however, they're bouncing back. Was yesterday's drop simply a buying ...